Adult Onset asthma and Inflammatory Sub-phenotypes

Adult Onset asthma and Inflammatory Sub-phenotypes - Adonis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33012

Enrollment

200

Registered

2009-09-15

Start date

2009-06-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adult onset asthma asthma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 to 75 years - Adult-onset asthma (i.e. asthma that started after the age of 18) - Physicians diagnosis of asthma 12 % predicted and 200 ml or airway hyperresponsiveness to inhaled methacholine (PC20

Exclusion criteria

Exclusion criteria: - Patients with smoking history > 10 packyears, fixed airflow obstruction (post bronchodilator FEV1

Design outcomes

Primary

Measure	Time frame
This is a descriptive study, without real outcome parameters. By performing cluster analysis, several phenotypes of recent late onset asthma will be defined. Potential risk factors are assessed at baseline (phase 1) and related to the change in lungfunction over time and exacerbation rate. Linear regression will be used to analyse the association between potential predicting factors and decline in FEV1 (ml.yr) and exacerbation rate during the follow-up. Logistic regression will be used to estimate RR/OR with 95% CI*s for accelerated decline in FEV1 and exacerbation rate.	—

Measure

Time frame

This is a descriptive study, without real outcome parameters. By performing cluster analysis, several phenotypes of recent late onset asthma will be defined. Potential risk factors are assessed at baseline (phase 1) and related to the change in lungfunction over time and exacerbation rate. Linear regression will be used to analyse the association between potential predicting factors and decline in FEV1 (ml.yr) and exacerbation rate during the follow-up. Logistic regression will be used to estimate RR/OR with 95% CI*s for accelerated decline in FEV1 and exacerbation rate.

—

Secondary

Measure	Time frame
n.v.t.	—

Countries

Netherlands

Outcome results